ACT

Vivus’s diet pill faces generic threat from Actavis

[Reuters] – Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus’s obesity drug Qsymia that was approved in July 2012. Actavis had filed a U.S. marketing application for its generic version of the diet pill, according moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee […]

Actavis Launches Generic Version of Catapres-TTS®

[PR Newswire] – DUBLIN, May 7, 2014 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim’s Catapres-TTS ® (Clonidine Transdermal System, USP, 0.1 mg/day, … moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee who Actavis is hiring next, click here to view […]

3 Drugs Stocks Dragging The Industry Down

moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee who Actavis is hiring next, click here to view […]

ACTAVIS PLC Files SEC form 10-Q, Quarterly Report

moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee who Actavis is hiring next, click here to view […]

Actavis Sues FDA Regarding Delay of Generic Celebrex® Approval

[PR Newswire] – DUBLIN, April 28, 2014 /PRNewswire/ — Actavis plc (ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency’s decision regarding its en moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee who Actavis is hiring next, […]

IBD 50: Actavis, Spirit Lead 5 Top Earnings On Tap

moreView todays social media effects on ACTView the latest stocks trending across Twitter. Click to view dashboardSee who Actavis is hiring next, click here to view […]